ruxolitinib + etoposide + dexamethasone + gemcitabine + pegaspargase + cisplatin

This is a multi-drug chemotherapy combination that includes the JAK inhibitor ruxolitinib, the topoisomerase II inhibitor etoposide, the corticosteroid dexamethasone, the nucleoside analog gemcitabine, the enzyme pegaspargase, and the platinum-based agent cisplatin. While the full combination is not specifically documented in the search results, components of this regimen have been studied together. Ruxolitinib combined with etoposide and dexamethasone (known as REC or R-DED) has been investigated for treating hemophagocytic lymphohistiocytosis (HLH) and lymphoma-associated hemophagocytic syndrome (LAHS). Ruxolitinib inhibits JAK1 and JAK2, which are involved in cytokine signaling and hematopoiesis, while etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, and dexamethasone provides anti-inflammatory effects.